Association of CYP2E1*6 polymorphism of gene CYP2E1 with the risk and severity of chronic hepatitis C
DOI:
https://doi.org/10.14739/2310-1210.2014.3.26034Keywords:
Hepatitis C virus, Disease Susceptibility, Genetic PolymorphismAbstract
Aim. The effectiveness of treatment of chronic hepatitis C (CHC) depends on the genetic characteristics of the patients. The aim was to analyze the association of CYP2E1*6 polymorphism with the risk of development and severity of CHC.
Methods and results. We determined the frequency of CYP2E1*6 polymorphism in 77 patients with CHC and 64 healthy donors using molecular genetic methods. Case histories were retrospectively analyzed. We did not find association between CYP2E1*6 polymorphism and the risk of CHC. The majority of patients with genotype CD had more frequently normal alanineaminotransferase levels than the patients with genotype DD (55,6 % vs 27,1 %, p = 0,026). Patients with genotype DD more often had different stages of liver fibrosis than the patients with genotype CD (34,5 % greater, p = 0,009, OR 4,24, 95% CI 1,37 – 12,93).
Conclusion.This indicates that the genotype DD of the gene CYP2E1 was associated with more severe course of CHC.References
- Blyum, H. E.(2005) Gepatit C: sovremennoe sostoyanie problemy [Hepatitis C: Present state of research]. Rossijskij zhurnal gastroe`nterologii, gepatologii, koloproktologii; 15(1), 20–25. [in Russian].
- Zhu, Y., & Chen, S. (2013) Antiviral treatment of hepatitis C virus infection and factors affecting efficacy. World J Gastroenterol, 21(47), 8963–8973. doi: 10.3748/wjg.v19.i47.8963.
- Park, S. H., Yang, J. M., Rim, K. S., Hwang, S. G., Kim, J. H., Kim, Y. S., et al. (2012). Efficacy and Tolerability of Peginterferon Alpha Plus Ribavirin in the Routine Daily Treatment of Chronic Hepatitis C Patients in Korea: A Multi-Center, Retrospective Observational Study. Gut and Liver, 6(1), 98.
- Liu, C. H., Liang, C. C., Liu, C. J., Tseng, T. C., Lin, C. L., Yang, S. S., et al. (2012) Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy. Antivir Ther, 17(3), 477–484.
- Wang, S., Zhu, A., Li, D., Wang, Z., Zhang, P., & Zhang, G. (2009). Frequencies of genotypes and alleles of the functional SNPs in CYP2C19 and CYP2E1 in mainland Chinese Kazakh, Uygur and Han populations. Journal of Human Genetics, 54(6), 372–375. doi:10.1038/jhg.2009.41.
- Nakajima, T., & Aoyama, T. (2000). Polymorphism of Drug-Metabolizing Enzymes in Relation to Individual Susceptibility to Industrial Chemicals. Industrial Health, 38(2), 143–152.
- Persson, I., Johansson, I., & Bergling, H. (1993) Genetic polymorphism of cytochrome P4502E1 in a Swedish population. Relationship to incidence of lung cancer. FEBS Lett, 319, 207–211. doi:10.1016/0014-5793(93)80547-8.
- Deka, M., Bose, M., Baruah, B., Deka, P. et al. (2010) Role of CYP2E1 gene polymorphisms association with hepatitis risk in Northeast India. World J. Gastroenterol, 14(38), 4800–4808.
- Kato, S., Shields, P. G., Caporaso, N. E., Hoover, R. N., Trump, B. F., Sugimura, H., et al. (1992) Cytochrome P450IIE1 genetic polymorphisms, racial variation, and lung cancer risk. Cancer Res, 1(23), 6712–6715.
- Fogel', F., & Motul'ski, A. (1990) Genetika cheloveka [Human Genetics]. Moscow: Mir. [in Russian].
Downloads
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. 
